This week, 6 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Shire PLC Sponsored ADR’s (SHPG) rating weakens this week, dropping to a F versus last week’s D. Shire PLC Sponsored ADR a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of SHPG stock.
Concordia Healthcare Corp. (CXRX) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CXRX stock.
Depomed, Inc. (DEPO) experiences a ratings drop this week, going from last week’s C to a D. Depomed, Inc. develops new and proprietary oral drug delivery technologies. The company also gets F’s in operating margin growth, earnings growth, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of DEPO stock.
Cumberland Pharmaceuticals Inc. (CPIX) declines this week from a D to a F. Cumberland Pharmaceuticals Inc. engages in the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States. The company also gets F’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CPIX stock.
This is a rough week for Ampio Pharmaceuticals, Inc. (AMPE). The company’s rating falls to D from the previous week’s C. Ampio Pharmaceuticals, Inc. engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AMPE stock.
Slipping from a C to a D rating, Merus Labs International Inc. (MSLI) takes a hit this week. Merus Labs International Inc. acquires and licenses niche branded pharmaceutical products in the United States and Canada. For more information, get Portfolio Grader’s complete analysis of MSLI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
